410,700 Shares in BridgeBio Oncology Therapeutics, Inc $BBOT Acquired by Catalio Capital Management LP

Catalio Capital Management LP bought a new position in shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 410,700 shares of the company’s stock, valued at approximately $5,142,000. Catalio Capital Management LP owned 0.51% of BridgeBio Oncology Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the company. Armistice Capital LLC increased its stake in shares of BridgeBio Oncology Therapeutics by 142.7% during the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $12,520,000 after buying an additional 588,000 shares during the period. Paradigm Biocapital Advisors LP increased its stake in shares of BridgeBio Oncology Therapeutics by 21.2% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after buying an additional 395,608 shares during the period. Laurion Capital Management LP increased its stake in shares of BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock worth $18,341,000 after buying an additional 419,138 shares during the period. Persistent Asset Partners Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $107,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $144,000. 54.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on BBOT shares. Canaccord Genuity Group started coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $23.00 target price on the stock. Wall Street Zen lowered shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, HC Wainwright increased their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

BridgeBio Oncology Therapeutics Price Performance

Shares of BridgeBio Oncology Therapeutics stock opened at $7.68 on Thursday. The stock has a market capitalization of $615.24 million, a price-to-earnings ratio of -3.75 and a beta of 0.29. BridgeBio Oncology Therapeutics, Inc has a 52 week low of $7.00 and a 52 week high of $14.87. The company has a 50 day moving average of $8.43.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. As a group, sell-side analysts predict that BridgeBio Oncology Therapeutics, Inc will post -2.32 earnings per share for the current year.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.